1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP)

Small biopharma story stocks just aren't paying off like they used to. Maybe there are just too many of them, with each one working on a medical breakthrough that's statistically unlikely to even come close to an approval.Every now and then, though, one of these companies defies the odds and gets a new drug on the market. CRISPR Therapeutics (NASDAQ: CRSP) is one of those companies, and what a game changer it introduced!The pharmaceutical industry has been working on DNA repair for years, albeit with little marketable success. That all changed in late 2023, however, when CRISPR Therapeutics' and developmental partner Vertex's drug Casgevy -- for the treatment of sickle cell disease -- became the FDA's first-ever approved CRISPR-based gene-editing therapy.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool